Targeting Opposing Immunological Roles of the Junctional Adhesion Molecule-A in Autoimmunity and Cancer.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 02 09 2020
accepted: 02 11 2020
entrez: 16 12 2020
pubmed: 17 12 2020
medline: 22 6 2021
Statut: epublish

Résumé

The junctional adhesion molecule-A (JAM-A) is a cell surface adhesion molecule expressed on platelets, epithelial cells, endothelial cells and leukocytes (e. g. monocytes and dendritic cells). JAM-A plays a relevant role in leukocyte trafficking and its therapeutic potential has been studied in several pathological conditions due to its capacity to induce leukocyte migration out of inflamed sites or infiltration into tumor sites. However, disruption of JAM-A pathways may worsen clinical pathology in some cases. As such, the effects of JAM-A manipulation on modulating immune responses in the context of different diseases must be better understood. In this mini-review, we discuss the potential of JAM-A as a therapeutic target, summarizing findings from studies manipulating JAM-A in the context of inflammatory diseases (e.g. autoimmune diseases) and cancer and highlighting described mechanisms.

Identifiants

pubmed: 33324419
doi: 10.3389/fimmu.2020.602094
pmc: PMC7723963
doi:

Substances chimiques

Inflammation Mediators 0
Junctional Adhesion Molecule A 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

602094

Subventions

Organisme : Versus Arthritis
ID : 19788
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : 19788
Pays : United Kingdom

Informations de copyright

Copyright © 2020 Bonilha, Benson, Brewer and Garside.

Déclaration de conflit d'intérêts

Author RB was employed by the company Antibody Analytics Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Biol Chem. 1990 Jun 15;265(17):10042-8
pubmed: 2351647
QJM. 2010 Mar;103(3):139-46
pubmed: 19926660
Blood. 2012 Apr 5;119(14):3352-60
pubmed: 22271446
J Immunol. 2004 Nov 15;173(10):6259-64
pubmed: 15528364
Thromb Haemost. 2007 Feb;97(2):272-81
pubmed: 17264957
Nature. 2014 Aug 21;512(7514):319-23
pubmed: 25119047
Mucosal Immunol. 2019 May;12(3):668-678
pubmed: 30745566
Leukemia. 2018 Mar;32(3):736-743
pubmed: 29064484
J Clin Invest. 2004 Sep;114(5):729-38
pubmed: 15343392
Eur J Biochem. 1999 Jul;263(1):104-11
pubmed: 10429193
Nat Rev Immunol. 2014 May;14(5):289-301
pubmed: 24722477
Physiol Genomics. 2006 May 16;25(3):435-49
pubmed: 16507782
J Biol Chem. 2000 Oct 6;275(40):30970-6
pubmed: 10913139
Semin Immunopathol. 2019 Nov;41(6):711-726
pubmed: 31732775
Curr Biol. 1997 Apr 1;7(4):R255-7
pubmed: 9162505
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Biochem Biophys Res Commun. 2009 Nov 20;389(3):543-9
pubmed: 19748485
Nat Immunol. 2002 Feb;3(2):151-8
pubmed: 11812992
J Biol Chem. 2004 Apr 16;279(16):16254-62
pubmed: 14749337
Front Microbiol. 2020 May 26;11:969
pubmed: 32528436
Carcinogenesis. 2015 Jan;36(1):41-8
pubmed: 25416560
Front Immunol. 2013 Sep 17;4:280
pubmed: 24062746
Atherosclerosis. 2019 May;284:92-101
pubmed: 30877938
Am J Pathol. 2006 Mar;168(3):1004-21
pubmed: 16507914
J Immunol. 2005 Mar 15;174(6):3668-75
pubmed: 15749905
PLoS One. 2011;6(6):e21242
pubmed: 21695058
Arthritis Res Ther. 2009;11(3):R64
pubmed: 19426483
Blood. 2014 Feb 27;123(9):1393-402
pubmed: 24300854
Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10634-9
pubmed: 16027360
Oncotarget. 2016 Jun 7;7(23):33887-900
pubmed: 27036044
Biophys J. 2009 Jan;96(1):285-93
pubmed: 18849408
Arthritis Rheum. 2006 Sep;54(9):2707-10
pubmed: 16948054
Nat Rev Immunol. 2003 Jul;3(7):582-90
pubmed: 12876560
Haematologica. 2021 Jul 01;106(7):1943-1956
pubmed: 32354870
J Cell Sci. 2006 Feb 1;119(Pt 3):490-9
pubmed: 16418218
Immunity. 2012 Sep 21;37(3):563-73
pubmed: 22981539
PLoS One. 2013 Oct 16;8(10):e77702
pubmed: 24147060
EMBO J. 2001 Aug 15;20(16):4391-8
pubmed: 11500366
Cancer Res. 2008 Apr 1;68(7):2194-203
pubmed: 18381425
Lancet. 2010 Sep 25;376(9746):1094-108
pubmed: 20870100
Blood. 2007 Sep 15;110(6):1848-56
pubmed: 17505016
J Hand Surg Am. 2008 Jan;33(1):49-58
pubmed: 18261665
Am J Hypertens. 2001 Jun;14(6 Pt 2):44S-54S
pubmed: 11411765
Mol Biol Cell. 2013 Apr;24(7):933-44
pubmed: 23389628
Arthritis Rheum. 1970 Nov-Dec;13(6):769-76
pubmed: 5495389
Mucosal Immunol. 2017 Mar;10(2):307-317
pubmed: 28120842
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5366-71
pubmed: 12697893
J Immunol. 1999 Jul 15;163(2):553-7
pubmed: 10395639
Int Immunol. 2007 Sep;19(9):1031-7
pubmed: 17804686
Cell. 2001 Feb 9;104(3):441-51
pubmed: 11239401
Int J Cancer. 2009 Sep 15;125(6):1343-51
pubmed: 19533747
Breast Cancer Res Treat. 2020 Jan;179(2):325-335
pubmed: 31650345
Front Immunol. 2016 Jun 02;7:213
pubmed: 27313578
Mol Biol Cell. 2019 Mar 1;30(5):566-578
pubmed: 30625033
Cancer Res. 2010 Mar 1;70(5):1759-65
pubmed: 20160037
J Cell Biol. 1998 Jul 13;142(1):117-27
pubmed: 9660867
J Transl Med. 2011 Jun 26;9:98
pubmed: 21703019
Biopolymers. 2014 Jul;102(4):322-34
pubmed: 24801754
Acta Neuropathol. 2007 Feb;113(2):177-86
pubmed: 17024496
Int J Rheum Dis. 2016 Feb;19(2):127-33
pubmed: 26230081
J Exp Med. 1999 Nov 1;190(9):1351-6
pubmed: 10544206
Blood. 2005 Jul 15;106(2):725-33
pubmed: 15827135
Blood. 2003 Sep 15;102(6):2108-14
pubmed: 12750158
Neuro Oncol. 2020 Nov 26;22(11):1591-1601
pubmed: 32592484
J Immunol. 2004 Oct 1;173(7):4443-51
pubmed: 15383575
Thromb Haemost. 2002 Nov;88(5):843-50
pubmed: 12428104
J Exp Med. 2007 Dec 24;204(13):3067-76
pubmed: 18039951
mBio. 2017 Feb 14;8(1):
pubmed: 28196955
Heart. 2018 Mar;104(6):460-467
pubmed: 29061690
Arterioscler Thromb Vasc Biol. 2003 Dec;23(12):2165-71
pubmed: 12958043
Mol Biol Cell. 2008 May;19(5):1862-72
pubmed: 18272784
Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):729-35
pubmed: 15681301
Mol Carcinog. 2019 Jul;58(7):1181-1193
pubmed: 30834573
J Virol. 2005 Jul;79(13):7967-78
pubmed: 15956543

Auteurs

Caio S Bonilha (CS)

College of Medical, Veterinary and Life Sciences, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.

Robert A Benson (RA)

College of Medical, Veterinary and Life Sciences, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.
Research and Development Department, Antibody Analytics Ltd., Newhouse, Lanarkshire, United Kingdom.

James M Brewer (JM)

College of Medical, Veterinary and Life Sciences, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.

Paul Garside (P)

College of Medical, Veterinary and Life Sciences, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH